Abbott, Teva Settle Patent Dispute Over TriCor, But Antitrust Claims Remain
Abbott Laboratories has settled a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd. over a generic version of Abbott's best-selling cholesterol treatment TriCor....To view the full article, register now.
Already a subscriber? Click here to view full article